Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Clinical trial-based cost-effectiveness analyses of antipsychotic use.

Polsky D, Doshi JA, Bauer MS, Glick HA.

Am J Psychiatry. 2006 Dec;163(12):2047-56. Review.

PMID:
17151153
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.

Montgomery JH, Byerly M, Carmody T, Li B, Miller DR, Varghese F, Holland R.

Control Clin Trials. 2004 Dec;25(6):598-612. Review.

PMID:
15588746
4.

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J; CATIE Study Investigators..

Am J Psychiatry. 2006 Dec;163(12):2080-9.

PMID:
17151158
5.

Assessing cost-effectiveness of drug interventions for schizophrenia.

Magnus A, Carr V, Mihalopoulos C, Carter R, Vos T.

Aust N Z J Psychiatry. 2005 Jan-Feb;39(1-2):44-54.

PMID:
15660705
6.

The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia.

Chen L, McCombs JS, Park J.

Value Health. 2008 Jan-Feb;11(1):34-43. doi: 10.1111/j.1524-4733.2007.00212.x.

7.

Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies.

Tunis SL, Johnstone BM, Kinon BJ, Barber BL, Browne RA.

Value Health. 2000 May-Jun;3(3):232-42. Review.

8.

Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .

Davies A, Vardeva K, Loze JY, L'italien GJ, Sennfalt K, Baardewijk Mv.

Curr Med Res Opin. 2008 Nov;24(11):3275-85. doi: 10.1185/03007990802507547 . Epub 2008 Oct 22.

PMID:
18947458
9.

Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.

Park T, Kuntz KM.

Value Health. 2014 Jun;17(4):310-9. doi: 10.1016/j.jval.2014.02.008. Epub 2014 May 10.

10.

Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.

Revicki DA.

Schizophr Res. 1999 Mar 1;35 Suppl:S101-9. Review.

PMID:
10190231
11.

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.

Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R.

Value Health. 2006 Mar-Apr;9(2):77-89.

12.

Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.

Yang YK, Tarn YH, Wang TY, Liu CY, Laio YC, Chou YH, Lee SM, Chen CC.

Psychiatry Clin Neurosci. 2005 Aug;59(4):385-94. Erratum in: Psychiatry Clin Neurosci. 2005 Oct;59(5):625-6. Tarn, Yeng Hui [corrected to Tarn, Yen-Huei].

13.

The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.

Achilla E, McCrone P.

Appl Health Econ Health Policy. 2013 Apr;11(2):95-106. doi: 10.1007/s40258-013-0016-2. Review.

PMID:
23494934
14.

Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.

Einarson TR, Vicente C, Zilbershtein R, Piwko C, Bø CN, Pudas H, Jensen R, Hemels ME.

Nord J Psychiatry. 2014 Aug;68(6):416-27. doi: 10.3109/08039488.2013.852243. Epub 2013 Nov 25.

PMID:
24274837
15.

Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.

Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT.

Curr Med Res Opin. 2004 Dec;20(12):1883-93.

PMID:
15701206
16.

[Cost-effectiveness of Antipsychotics in the Maintenance Treatment of Schizophrenia in Colombia].

Quitian Reyes H, Arciniegas Barrera JA, Bohórquez Peñaranda A, Gómez Restrepo C.

Rev Colomb Psiquiatr. 2016 Apr-Jun;45(2):67-74. doi: 10.1016/j.rcp.2015.05.013. Epub 2015 Jul 4. Spanish.

PMID:
27132755
17.
18.

Cost-effectiveness of atypical antipsychotics in chronic schizophrenia.

Amin S.

Hosp Med. 1999 Jun;60(6):410-3. Review.

PMID:
10492711
19.

Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.

Lindner LM, Marasciulo AC, Farias MR, Grohs GE.

Rev Saude Publica. 2009 Aug;43 Suppl 1:62-9.

20.

A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany.

Beard SM, Maciver F, Clouth J, Rüther E.

Eur J Health Econ. 2006 Sep;7(3):165-72.

PMID:
16896764

Supplemental Content

Support Center